Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Instagram Outage Disrupts Thousands of U.S. Users 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
GAITHERSBURG, Md., Oct. 19, 2017 -- Emergent BioSolutions (NYSE:EBS) will release its financial results for the third quarter and nine months of 2017 immediately after market close on Thursday, November 2, 2017. The company will also host a conference call at 5:00 pm (Eastern Time) at which time members of management will discuss these results, as well as recent business developments, revenue and net income guidance for full year 2017 and revenue guidance for fourth quarter 2017.
This conference call can be accessed live by telephone or via webcast:
Live Teleconference Information:
Dial in number: (855) 766-6521
Conference ID: 29706026
Live Webcast Information:
Visit https://edge.media-server.com/m6/p/dvysvtww for the live webcast feed.
A replay of the call can be accessed on Emergent’s website emergentbiosolutions.com under “Investors.”
About Emergent BioSolutions
Emergent BioSolutions Inc. is a global life sciences company seeking to protect and enhance life by focusing on providing specialty products for civilian and military populations that address accidental, intentional, and naturally emerging public health threats. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at emergentbiosolutions.com. Follow us @emergentbiosolu.
Investor Contact:
Robert G. Burrows
Vice President, Investor Relations
240-631-3280
[email protected]
Media Contact:
Lynn Kieffer
Vice President, Corporate Communications
240-631-3391
[email protected]
